ArticleOncoimmunology2020

TCB2, a new anti-human interleukin-2 antibody, facilitates heterodimeric IL-2 receptor signaling and improves anti-tumor immunity.

Jun-Young Lee et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.